Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

Novo Nordisk A/S149 enrolled

Overview

This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

149

Conditions

Growth Hormone Disorder Pituitary Dwarfism

Interventions

somatropinDRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ages 3-15 * Presence of growth failure indicated by height standard deviation score less than equal to -2 * Body mass index greater than or equal to 25th percentile for height age * IGF concentration less than or equal to 33rd percentile

Locations (27)

Outcomes

Primary Outcomes

Change in height standard deviation score

Time frame: 12 months

Secondary Outcomes

12 months change in height standard deviation score adjusted for parent height z-score

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.